+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1



A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1



Plos One 8(12): E83509



The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant potential to treat T2D. The peptide, referred to as Diapin, is comprised of three natural L-amino acids, GlyGlyLeu. Glucose tolerance tests showed that oral administration of Diapin effectively lowered blood glucose after oral glucose loading in both normal C57BL/6J mice and T2D mouse models, including KKay, db/db, ob/ob mice, and high fat diet-induced obesity/T2D mice. In addition, Diapin treatment significantly reduced casual blood glucose in KKay diabetic mice in a time-dependent manner without causing hypoglycemia. Furthermore, we found that plasma GLP-1 and insulin levels in diabetic models were significantly increased with Diapin treatment compared to that in the controls. In summary, our findings establish that a peptide with minimum of three amino acids can improve glucose homeostasis and Diapin shows promise as a novel pharmaceutical agent to treat patients with T2D through its dual effects on GLP-1 and insulin secretion.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 051279842

Download citation: RISBibTeXText

PMID: 24386218


Related references

Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism: Clinical and Experimental 59(2): 285-292, 2010

Insulin glargine lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia. Journal of Pediatric Endocrinology & Metabolism 13(Supplement 4): 1217, 2000

Insulin glargine lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycaemia. Diabetologia 42(SUPPL 1): A235, 1999

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43(2): 204-211, 1994

Adenovirus-mediated overexpression of the glucokinase regulatory protein lowers fasting blood glucose levels and improves glucose tolerance in rodent models of type 2 diabetes. Diabetes 50(Supplement 2): A322, 2001

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus. Annals of Internal Medicine 169(6): 394-397, 2018

The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetes. Diabetes Research 1(4): 187-193, 1984

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabetic Medicine 23(7): 729-735, 2006

IV GLP-1 lowers blood glucose levels in NIDDM patients regardless of fasting glucose, BMI, and insulin capacity. Diabetologia 40(SUPPL 1): A129, 1997

Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. Journal of Biological Chemistry 284(49): 33833-33840, 2009

Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice. European Journal of Pharmacology 578(2-3): 359-364, 2007

Cathepsin S inhibition lowers blood glucose levels in mice. Diabetologia 57(8): 1674-1683, 2015

Standard deviation of fasting blood glucose response to insulin is correlated to glycohemoglobin levels in Type I, but not Type II diabetes mellitus. Diabetes 48(SUPPL 1): A344, 1999

Behavior of C-peptide, insulin and glucose levels in blood during conditions of evaluating selected antihypertensive drugs in patients with hypertension and non-insulin-dependent diabetes (type 2). Polskie Archiwum Medycyny Wewnetrznej 89(6): 445-455, 1993

Self-Monitoring of Blood Glucose Levels in Persons with Type 2 Diabetes Not Requiring Insulin: Routine Use Is Not Recommended. Canadian Journal of Diabetes 35(1): 19-20, 2011